A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis

Trial Profile

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs ALKS 8700 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms EVOLVE-1; EVOLVE-MS-1
  • Sponsors Alkermes plc
  • Most Recent Events

    • 02 Jun 2017 Planned number of patients changed from 800 to 935.
    • 28 Apr 2017 Trial design presented at the 69th Annual Meeting of the American Academy of Neurology
    • 13 Feb 2017 Planned number of patients changed from 600 to 800.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top